Physician profile
Lily Ho
NPI 1558561878
$1,252.24
in general payments reported to CMS, 2019-2025
10 companies · $228 in 2025
The $228 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $59.68 · 2022: $24.91 · 2023: $283 · 2024: $241 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $304.65 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $206.88 | 2019-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $166.44 | 2022-2025 | Verquvo |
| Pfizer INC. | $150.28 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $123.25 | 2019-2025 | |
| Amgen INC. | $89.88 | 2019-2025 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $81.83 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.77 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $43.64 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $15.62 | 2025 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lily Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.